AstraZeneca plc (AZN) PT Lowered to GBX 3,800 at Goldman Sachs Group, Inc. (The)
AstraZeneca plc (LON:AZN) had its price objective trimmed by Goldman Sachs Group, Inc. (The) from GBX 3,900 ($50.44) to GBX 3,800 ($49.15) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.
AZN has been the topic of a number of other research reports. Barclays PLC restated an overweight rating and set a GBX 6,000 ($77.60) price target on shares of AstraZeneca plc in a report on Thursday, May 4th. Shore Capital reiterated a sell rating on shares of AstraZeneca plc in a report on Thursday, May 4th. HSBC Holdings plc reiterated a reduce rating and set a GBX 4,200 ($54.32) target price on shares of AstraZeneca plc in a report on Friday, May 5th. J P Morgan Chase & Co reissued a neutral rating on shares of AstraZeneca plc in a research report on Thursday, May 11th. Finally, Jefferies Group LLC dropped their price target on AstraZeneca plc from GBX 4,900 ($63.37) to GBX 4,700 ($60.79) and set a hold rating on the stock in a research report on Friday, May 12th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of GBX 4,892.19 ($63.27).
AstraZeneca plc (LON AZN) opened at 4592.50 on Wednesday. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The firm’s market cap is GBX 58.14 billion. The firm has a 50-day moving average price of GBX 4,644.61 and a 200-day moving average price of GBX 4,870.16.
ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) PT Lowered to GBX 3,800 at Goldman Sachs Group, Inc. (The)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/02/astrazeneca-plc-azn-pt-lowered-to-gbx-3800-at-goldman-sachs-group-inc-the.html.
The firm also recently disclosed a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date is Thursday, August 10th. This represents a yield of 1.35%.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.52) per share, with a total value of £1,704.30 ($2,204.22).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.